Elevated Serum Osteoprotegerin is Associated with Reduced Risks of Albuminuria and CKD Progression in Patients with Type 2 Diabetes

References

• Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88(5):950–957. doi:10.1038/ki.2015.230
   PubMed Web of Science ®Google Scholar
• Wakasugi M, Kazama JJ, Narita I. Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan. Ther Apher Dial. 2015;19(3):201–206. doi:10.1111/1744-9987.12266
   Web of Science ®Google Scholar
• Almutairi FM, Al-Duais MA, Shalaby KA, et al. Analysis of patients with end-stage renal disease on dialysis in Tabuk City, Saudi Arabia: a single-center, three-year retrospective study. Saudi J Kidney Dis Transpl. 2017;28(2):349–354. doi:10.4103/1319-2442.202769
   Web of Science ®Google Scholar
• Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int. 2013;84(3):622–623. doi:10.1038/ki.2013.243
   PubMed Web of Science ®Google Scholar
• Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–906. doi:10.1056/NEJMc1602469
   PubMed Web of Science ®Google Scholar
• Draznin B, Aroda VR, Bakris G, et al. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–S184.
   PubMedGoogle Scholar
• Harper E, Forde H, Davenport C, et al. Vascular calcification in type-2 diabetes and cardiovascular disease: integrative roles for OPG, RANKL and TRAIL. Vascul Pharmacol. 2016;82:30–40. doi:10.1016/j.vph.2016.02.003
   Web of Science ®Google Scholar
• Wang ST, Zhang CY, Zhang CM, et al. The plasma osteoprotegerin level and osteoprotegerin expression in renal biopsy tissue are increased in type 2 diabetes with nephropathy. Exp Clin Endocrinol Diabetes. 2015;123(2):106–111. doi:10.1055/s-0034-1390447
   Web of Science ®Google Scholar
• Duan P, Yang M, Wei M, et al. Serum osteoprotegerin is a potential biomarker of insulin resistance in Chinese postmenopausal women with prediabetes and type 2 diabetes. Int J Endocrinol. 2017;2017:8724869. doi:10.1155/2017/8724869
   Web of Science ®Google Scholar
• Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C. Osteoprotegerin and diabetes-associated pathologies. Curr Mol Med. 2011;11(5):401–416. doi:10.2174/156652411795976565
   Web of Science ®Google Scholar
• Xiang GD, Pu JH, Zhao LS, et al. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med. 2009;26(4):397–403. doi:10.1111/j.1464-5491.2009.02683.x
   Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Mohamed GB, Abdel-Latif EA. Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. Saudi J Kidney Dis Transpl. 2011;22(5):955–962.
   Google Scholar
• Niu Y, Yang Z, Li X, et al. Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study. BMC Endocr Disord. 2015;15:75. doi:10.1186/s12902-015-0067-5
   Web of Science ®Google Scholar
• Kamińska J, Stopiński M, Mucha K, et al. Circulating osteoprotegerin in chronic kidney disease and all-cause mortality. Int J Gen Med. 2021;14:2413–2420. doi:10.2147/IJGM.S302251
   Web of Science ®Google Scholar
• Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin in vascular calcification and bone metabolism: the basis for developing new therapeutics. Calcif Tissue Int. 2019;105(3):239–251. doi:10.1007/s00223-019-00573-6
   Web of Science ®Google Scholar
• Hénaut L, Sanchez-Nino MD, Aldamiz-Echevarría Castillo G, et al. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. Expert Opin Ther Targets. 2016;20(1):89–105. doi:10.1517/14728222.2015.1081685
   PubMed Web of Science ®Google Scholar
• Kang YH, Jin JS, Son SM. Long term effect of high glucose and phosphate levels on the OPG/RANK/RANKL/TRAIL system in the progression of vascular calcification in rat aortic smooth muscle cells. Korean J Physiol Pharmacol. 2015;19(2):111–118. doi:10.4196/kjpp.2015.19.2.111
   Web of Science ®Google Scholar
• Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1–17. doi:10.1016/j.ejcb.2008.06.004
   Web of Science ®Google Scholar
• Znorko B, Oksztulska-Kolanek E, Michałowska M, et al. Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review. Adv Med Sci. 2017;62(1):52–64. doi:10.1016/j.advms.2016.08.001
   Web of Science ®Google Scholar
• Liu S, Shi W, Xiao H, et al. Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One. 2012;7(7):e41331. doi:10.1371/journal.pone.0041331
   Web of Science ®Google Scholar
• Ke G, Chen X, Liao R, et al. Receptor activator of NF-κB mediates podocyte injury in diabetic nephropathy. Kidney Int. 2021;100(2):377–390. doi:10.1016/j.kint.2021.04.036
   PubMed Web of Science ®Google Scholar
• Chen XW, Du XY, Wang YX, et al. Irbesartan ameliorates diabetic nephropathy by suppressing the RANKL-RANK-NF-κB pathway in type 2 diabetic db/db mice. Mediators Inflamm. 2016;2016:1405924. doi:10.1155/2016/1405924
   Web of Science ®Google Scholar
• Wittrant Y, Theoleyre S, Couillaud S, et al. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res. 2004;293(2):292–301. doi:10.1016/j.yexcr.2003.10.016
   Web of Science ®Google Scholar
• Min JK, Cho YL, Choi JH, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood. 2007;109(4):1495–1502. doi:10.1182/blood-2006-06-029298
   Web of Science ®Google Scholar
• Keynan S, Hirshberg B, Levin-Iaina N, et al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int. 2000;58(2):740–747. doi:10.1046/j.1523-1755.2000.00220.x
   PubMed Web of Science ®Google Scholar
• Chang YH, Lin KD, He SR, et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism. 2011;60(8):1064–1069. doi:10.1016/j.metabol.2010.11.002
   PubMed Web of Science ®Google Scholar
• Chang WW, Liang W, Yao XM, et al. Tumour necrosis factor-related apoptosis-inducing ligand expression in patients with diabetic nephropathy. J Renin Angiotensin Aldosterone Syst. 2018;19(3):1470320318785744. doi:10.1177/1470320318785744
   Web of Science ®Google Scholar
• Carlsson AC, Ingelsson E, Sundström J, et al. Use of proteomics to investigate kidney function decline over 5 years. Clin J Am Soc Nephrol. 2017;12(8):1226–1235. doi:10.2215/CJN.08780816
   Web of Science ®Google Scholar
• Sanchez-Nino MD, Benito-Martin A, Goncalves S, et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm. 2010;2010:182958. doi:10.1155/2010/182958
   Web of Science ®Google Scholar
• Chen C, Wang C, Hu C, et al. Normoalbuminuric diabetic kidney disease. Front Med. 2017;11(3):310–318. doi:10.1007/s11684-017-0542-7
   PubMed Web of Science ®Google Scholar
• Song N, Thaiss F, Guo L. NFκB and kidney injury. Front Immunol. 2019;10:815. doi:10.3389/fimmu.2019.00815
   PubMed Web of Science ®Google Scholar
• Chen J, Li D. Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling. Int Immunopharmacol. 2018;55:1–8. doi:10.1016/j.intimp.2017.11.043
   PubMed Web of Science ®Google Scholar
• Dirice E, Kahraman S, Elpek GO, et al. TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice. Exp Diabetes Res. 2011;2011:625813. doi:10.1155/2011/625813
   PubMedGoogle Scholar
• Sanlioglu AD, Dirice E, Elpek O, et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas. 2009;38(2):154–160. doi:10.1097/MPA.0b013e31818db9e3
   Web of Science ®Google Scholar
• Adachi T, Sugiyama N, Gondai T, et al. Blockade of death ligand TRAIL inhibits renal ischemia reperfusion injury. Acta Histochem Cytochem. 2013;46(6):161–170. doi:10.1267/ahc.13022
   PubMed Web of Science ®Google Scholar
• Elsamahy MH, Elhenawy YI, Nawar MM. Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria. J Diabetes Complications. 2015;29(4):563–567. doi:10.1016/j.jdiacomp.2015.02.008
   Web of Science ®Google Scholar
• Oh TR, Myeong C, Song SH, et al. Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study). Kidney Res Clin Pract. 2022;41(2):200–208. doi:10.23876/j.krcp.21.173
   Web of Science ®Google Scholar
• Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–1356. doi:10.1093/ndt/gfv081
   PubMed Web of Science ®Google Scholar
• Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010;107(4):466–475. doi:10.1161/CIRCRESAHA.110.216846
   PubMed Web of Science ®Google Scholar
• Singh DK, Winocour P, Summerhayes B, et al. Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function. Diabetes Res Clin Pract. 2012;97(1):158–165. doi:10.1016/j.diabres.2012.01.038
   Web of Science ®Google Scholar
• Lello S, Capozzi A, Scambia G. Osteoporosis and cardiovascular disease: an update. Gynecol Endocrinol. 2015;31(8):590–594. doi:10.3109/09513590.2015.1041908
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104. doi:10.1038/ki.2010.531
   PubMed Web of Science ®Google Scholar
• Oh KH, Park SK, Park HC, et al. KNOW-CKD (Korean cohort study for outcome in patients with chronic kidney disease): design and methods. BMC Nephrol. 2014;15:80. doi:10.1186/1471-2369-15-80
   Web of Science ®Google Scholar
• Ekinci EI, Jerums G, Skene A, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36(11):3620–3626. doi:10.2337/dc12-2572
   PubMed Web of Science ®Google Scholar